Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004 Jun 01; 10(11):3885-96.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.